Why Analysts are Rating Alkermes (ALKS) a Buy

Group 1 - Alkermes plc (NASDAQ:ALKS) is considered a promising mid-cap healthcare stock under $50, with a consensus of 11 Buy ratings and 4 Holds from 15 analysts, indicating a median 1-year price target of $46.17, representing a 62.3% upside potential [1] - The company plans to acquire Avadel, which has a topline of approximately $275 million, as part of its strategy to enter the hypersomnolence market and launch alixorexton, an oral drug for complex sleep disorders [2] - Analyst David Amsellem from Piper Sandler reaffirmed a Buy rating for Alkermes with a price target of $45, suggesting more than 58% upside potential for investors [3] Group 2 - Alkermes is a biopharmaceutical company focused on developing and commercializing innovative medicines for neurological disorders, utilizing proprietary technologies for formulations aimed at psychiatric conditions [4]